Compounded semaglutide and tirzepatide should not be treated as generic substitutes a clinic can routinely source and market. As of the August 2026 review, these products are not on FDA’s shortage list, and FDA has ended the shortage-based enforcement-discretion periods that previously allowed broad compounding. Verify the current status before building a business model around it.
Open the full explanation4 sections and primary sources
What changed for compounded GLP-1 medications?
For §503A compounding, federal law restricts regular or inordinate compounding of products that are essentially copies of commercially available drugs. FDA has indicated an individual-patient compounded product may fall outside the “essentially a copy” restriction when the prescriber determines and documents a change that produces a significant difference for that identified patient — assuming the other statutory conditions are met.
Why should a clinic owner care about the essentially-a-copy rule?
A model built on “everyone gets compounded GLP-1 because it’s cheaper” is not the same as “a prescriber identifies an individual patient need that supports a compounded preparation under the applicable framework.” That distinction is commercially and legally important.
What safety concerns has FDA reported about compounded GLP-1s?
FDA has reported concerns involving compounded semaglutide and tirzepatide — fraudulent labels, pharmacies named that did not make the product, improper shipping, dosing errors, and salt forms — and has stepped up enforcement against marketing compounded products as “generic,” “the same as,” or “clinically proven equivalent” to the approved drugs. Review your clinic’s marketing accordingly.
Owner takeaway
Compounded GLP-1 is no longer a simple shortage workaround. You need a defensible patient-specific prescribing, pharmacy, sourcing, product-verification, and marketing structure — and you should re-check current FDA status before any product decision.